SoftOx Wound Infection Remover

Today, 40 million people globally live with chronic wounds. In addition to chronic wounds, 150 million acute wounds are reported annually from health care institutions that could become chronic without proper and timely treatment (MedMarket Diligence 2015 study). One of the largest problem healthcare faces today is the formation of biofilms in infection sites. It is estimated that biofilm infections represent 80% of all human infections and facilitate the development of antimicrobial resistance in wounds. Socio-economically, the direct cost of treating chronic wounds is estimated to accumulate to 5,6% of the total national healthcare expenditure; corresponding to €200 Bn per year globally. Market data shows that the global wound treatment market has a size of €9.25 Bn. SoftOx’ “WoundHealer” product will remove infection in wounds. There are many products and solutions in this market segment, but the performance of SoftOx’ products have proven a superior performance compares to the SoA products in preclinical studies. It has been shown that SoftOx wound care solution also penetrates biofilm matrix also below the wound bed, killing microbes and thus enables the host immune defense to regain control. The SoftOx technology is based on a combination of two highly active chemical agents with antimicrobial properties, namely ethanoic acid and hypochlorous acid. They have succeeded in stabilizing hypochlorous acid, by using their patented production process and mixing device, resulting in sustainable concentrations of hypochlorous acid with best-in-class antimicrobial effects. The company’s intellectual properties (IP’s) are well-protected through a broad patent application portfolio in the US, EU, Canada, EFTA and Turkey. The total market volume for wound irrigation solutions is estimated to be 36 million litres. With a price of €35/litre, the global economic potential for WoundHealer in the relevant segments is estimated to be €1.2 Bn.